Neurocrine Biosciences shares jump on fresh long-term CRENESSITY data catalyst

Neurocrine Biosciences (NBIX) is up 6.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a company update highlighting new two-year data for CRENESSITY (crinecerfont) that will be presented at ENDO 2026. Investors often re-rate commercial-stage biotech names on longer-term durability and patient-reported outcomes, particularly when a launch asset’s real-world adoption story is still being established.

Details:

The company announced it will present new two-year CRENESSITY data on key clinical measures and patient-reported outcomes at the ENDO 2026 meeting.

CRENESSITY is used in congenital adrenal hyperplasia (CAH), and longer-duration outcomes can influence physician confidence, payer discussions, and expectations for sustained growth.

In its most recent quarterly update, Neurocrine emphasized strong commercial momentum across its portfolio and continued investment behind the CRENESSITY launch.

Neurocrine also recently completed its acquisition of Soleno Therapeutics, adding VYKAT XR and expanding its endocrinology/rare disease footprint, which could be supporting broader bullish positioning.

Sources:

Neurocrine Biosciences (press release), SEC (8-K filing), Neurocrine Biosciences (quarterly results release)

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$NBIX Insider Trading Activity

$NBIX insiders have traded $NBIX stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.

Here’s a breakdown of recent trading of $NBIX stock by insiders over the last 6 months:

KEVIN CHARLES GORMAN sold 245,088 shares for an estimated $37,824,872
KYLE GANO (Chief Executive Officer) has made 0 purchases and 2 sales selling 36,400 shares for an estimated $4,830,458.
JUDE ONYIA (Chief Scientific Officer) has made 0 purchases and 2 sales selling 22,000 shares for an estimated $3,473,575.
RICHARD F POPS sold 15,000 shares for an estimated $2,364,760
GARY A LYONS sold 15,000 shares for an estimated $2,289,082
LESLIE V NORWALK has made 0 purchases and 3 sales selling 10,000 shares for an estimated $1,536,302.
DARIN LIPPOLDT (Chief Legal Officer) sold 4,376 shares for an estimated $698,615
DAVID W. BOYER (Chief Corp. Affairs Officer) sold 3,888 shares for an estimated $609,023
INGRID DELAET (Chief Regulatory Officer) sold 2,261 shares for an estimated $354,321

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$NBIX Hedge Fund Activity

We have seen 371 institutional investors add shares of $NBIX stock to their portfolio, and 361 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

TWO SIGMA INVESTMENTS, LP added 2,075,759 shares (+210.8%) to their portfolio in Q1 2026, for an estimated $273,460,490
PRICE T ROWE ASSOCIATES INC /MD/ removed 1,720,984 shares (-91.9%) from their portfolio in Q1 2026, for an estimated $226,722,432
BELLEVUE GROUP AG removed 1,698,658 shares (-99.7%) from their portfolio in Q1 2026, for an estimated $223,781,204
AQR CAPITAL MANAGEMENT LLC added 1,667,261 shares (+51.0%) to their portfolio in Q1 2026, for an estimated $219,644,964
VESTAL POINT CAPITAL, LP added 1,250,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $164,675,000
MILLENNIUM MANAGEMENT LLC added 804,581 shares (+181.7%) to their portfolio in Q1 2026, for an estimated $105,995,500
TWO SIGMA ADVISERS, LP added 693,819 shares (+466.4%) to their portfolio in Q4 2025, for an estimated $98,404,348

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$NBIX Analyst Ratings

Wall Street analysts have issued reports on $NBIX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 02/12/2026
Needham issued a "Buy" rating on 02/12/2026
Truist Securities issued a "Buy" rating on 01/08/2026
Stifel issued a "Buy" rating on 12/11/2025

To track analyst ratings and price targets for $NBIX, check out Quiver Quantitative's $NBIX forecast page.

$NBIX Price Targets

Multiple analysts have issued price targets for $NBIX recently. We have seen 20 analysts offer price targets for $NBIX in the last 6 months, with a median target of $184.0.

Here are some recent targets:

Corinne Johnson from Goldman Sachs set a target price of $213.0 on 06/02/2026
Brian Abrahams from RBC Capital set a target price of $183.0 on 05/29/2026
Jeffrey Walch from Bernstein set a target price of $221.0 on 05/22/2026
Anupam Rama from JP Morgan set a target price of $185.0 on 05/08/2026
Danielle Brill from Truist Securities set a target price of $155.0 on 05/07/2026
Yatin Suneja from Guggenheim set a target price of $175.0 on 05/06/2026
Yigal Nochomovitz from Citigroup set a target price of $246.0 on 05/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.